From the Center on Drug and Alcohol Research (MRL, SLW), the College of Medicine Departments of Behavioral Science (MRL, SLW), Psychiatry (MRL, SLW), and Pharmacology (SLW), and the College of Pharmacy Department of Pharmaceutical Sciences (SLW), University of Kentucky, Lexington.
Send correspondence and reprint requests to Michelle R. Lofwall, MD, Departments of Behavioral Science and Psychiatry, Center on Drug and Alcohol Research, University of Kentucky College of Medicine, 515 Oldham Ct, Lexington, KY 40502. E-mail: [email protected].
Supported by, in part, National Institute on Drug Abuse grant R01DA016718 and R01DA033932 (SLW). Drs Lofwall and Walsh are on the steering committee for the European Quality Patient Care Network that is part of PCM Scientific (a British educational company) and have received payment from PCM Scientific for developing educational materials and giving educational talks. In addition, Dr Walsh has received payment for chairing and organizing a 3-day conference supported by PCM Scientific through an unrestricted grant from Reckitt Benckiser. Dr Lofwall has been a consultant for Orexo Pharmaceuticals and has had research contract funding from CRS Associates in the past. Dr Walsh has received payment for service on a Safety Advisory Board for MEDA Pharmaceuticals and for service on the American Society of Addiction Medicine Board Exam Committee. She has served as a consultant for DemeRx, Eli Lilly and Co, KSI Consulting, MedSignals, and Cephalon. She has received honoraria and travel reimbursement for participating in educational meetings for physicians through Real Science Communications and the University of Kentucky.
The authors declare no conflicts of interest.
Received November 26, 2013
Accepted March 30, 2014
